ClinicalTrials.gov record
Completed Phase 3 Interventional

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

ClinicalTrials.gov ID: NCT04246177

Public ClinicalTrials.gov record NCT04246177. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 20, 2026, 11:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3 Multicenter, Randomized, Double-blinded, Active-controlled, Clinical Study to Evaluate the Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (LEAP-012)

Study identification

NCT ID
NCT04246177
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Enrollment
479 participants

Conditions and interventions

Interventions

  • IV Placebo Drug
  • Lenvatinib Drug
  • Oral Placebo Drug
  • Pembrolizumab Biological
  • TACE Procedure

Drug · Biological · Procedure

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 21, 2020
Primary completion
Aug 18, 2025
Completion
Mar 25, 2026
Last update posted
May 13, 2026

2020 – 2026

United States locations

U.S. sites
27
U.S. states
20
U.S. cities
25
Facility City State ZIP Site status
Arizona Oncology Associates PC- HOPE ( Site 0770) Tucson Arizona 85711
Scripps Clinic Torrey Pines ( Site 0714) La Jolla California 92037
USC Norris Comprehensive Cancer Center ( Site 0717) Los Angeles California 90033
UCLA Hematology/Oncology - Santa Monica ( Site 0720) Los Angeles California 90404
UC Irvine Health ( Site 0718) Orange California 92868
Yale Cancer Center ( Site 0724) New Haven Connecticut 06510
Tampa General Hospital ( Site 0764) Tampa Florida 33606
Mountain States Tumor Institute ( Site 0773) Boise Idaho 83712
University of Iowa Hospital and Clinics ( Site 0729) Iowa City Iowa 52242
University of Kansas Cancer Center ( Site 0731) Westwood Kansas 66205
University of Louisville ( Site 0757) Louisville Kentucky 40202
Tulane Medical Center ( Site 0787) New Orleans Louisiana 70112
University Medical Center New Orleans ( Site 0733) New Orleans Louisiana 70112
Henry Ford Hospital-GI/Hepatology Research ( Site 0735) Detroit Michigan 48202
Saint Louis University ( Site 0769) St Louis Missouri 63110
University of New Mexico Comprehensive Cancer Center ( Site 0805) Albuquerque New Mexico 87106
Monter Cancer Center ( Site 0780) Lake Success New York 11042
Icahn School of Medicine at Mount Sinai ( Site 0744) New York New York 10029
Wake Forest Baptist Health ( Site 0741) Winston-Salem North Carolina 27157
University of Cincinnati Medical Center ( Site 0791) Cincinnati Ohio 45219
The Ohio State University Wexner Medical Center ( Site 0759) Columbus Ohio 43210
ProMedica Flower Hospital ( Site 0796) Sylvania Ohio 43560
Stephenson Cancer Center ( Site 0745) Oklahoma City Oklahoma 73104
OHSU Center for Health & Healing ( Site 0746) Portland Oregon 97239
Penn State Hershey Medical Center ( Site 0766) Hershey Pennsylvania 17033-0850
Houston Methodist Research Institute ( Site 0784) Houston Texas 77030
Edwards Comprehensive Cancer Center ( Site 0786) Huntington West Virginia 25701

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 178 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04246177, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted May 13, 2026 · Synced May 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04246177 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →